No Bladder-Cancer Risk With Pioglitazone, Says Takeda No Bladder-Cancer Risk With Pioglitazone, Says Takeda
Takeda has submitted new data to regulatory authorities worldwide that it says show there is no bladder-cancer risk with its diabetes drug pioglitazone. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 4, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Actos Lawsuit News: Federal Judge Won’t Dismiss $9 Billion Verdict in...
The Firm is evaluating Actos lawsuits on behalf of individuals who developed bladder cancer, allegedly due to long-term use of the Type 2 diabetes drug.(PRWeb August 31, 2014)Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb12133446.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 1, 2014 Category: Pharmaceuticals Source Type: news
Takeda to submit data for pioglitazone containing medicines including ACTOS
Takeda Pharmaceutical Company Limited announced the completion of the post-marketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities including the United States Food and Drug Administration, the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 1, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Diabetes Oncology ACTOS Latest News pioglitazone pioglitazone HCl regulatory bodies takeda Source Type: news
No Actos Cancer Link in Long Term Data
(MedPage Today) -- Topline results from a 10-year analysis of diabetic patients treated with pioglitazone (Actos) indicated no increased risk of bladder cancer, even with long-term use, the drug's manufacturer said. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 29, 2014 Category: Cardiology Source Type: news
Takeda Says No Actos Cancer Link in 10-Year Data
(MedPage Today) -- Topline results from a 10-year analysis of diabetic patients treated with pioglitazone (Actos) indicated no increased risk of bladder cancer, even with long-term use, the drug's manufacturer said. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 29, 2014 Category: Urology & Nephrology Source Type: news
Takeda, Lilly lose bid to overturn $9 billion award for hiding cancer risk
(Reuters) - Takeda Pharmaceutical Co Ltd and Eli Lilly & Co lost a bid to overturn a combined $9 billion punitive damage award by a U.S. jury for hiding cancer risks associated with their Actos diabetes drug, according to a court ruling. (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Plaintiffs Awarded $9 Billion in Punitive Damages in Actos Litigation...
Takeda Pharmaceuticals Co. and Eli Lilly & Co. moving for new trial(PRWeb August 04, 2014)Read the full story at http://www.prweb.com/releases/2014/08/prweb12066744.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 5, 2014 Category: Pharmaceuticals Source Type: news
Vipidia™, fixed-dose combinations Vipdomet™ and Incresync™ label updates
Takeda Pharmaceuticals International GmbH ('Takeda') has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia™ (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet™ (alogliptin and metformin) and Incresync™ (alogliptin and pioglitazone). (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 29, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Diabetes Latest News Source Type: news
Positive CHMP opinions for label updates to Vipidia™ and fixed-dose combinations Vipdomet™ and Incresync™
Takeda Pharmaceuticals International GmbH ('Takeda') has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia™ (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet™ (alogliptin and metformin) and Incresync™ (alogliptin and pioglitazone). (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 29, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Diabetes Latest News Source Type: news
Diabetes Drug Linked to Lower Dementia RiskDiabetes Drug Linked to Lower Dementia Risk
Long-term use of pioglitazone may protect against dementia, possibly by suppressing neuroinflammation, new observational data hint. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 24, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Blue Cross and Blue Shield of Massachusetts Files Actos Lawsuit
In light of Blue Cross and Blue Shield of Massachusetts’ recent Actos lawsuit, Flood Law Group announces it is investigating potential Actos claims.(PRWeb June 20, 2014)Read the full story at http://www.prweb.com/releases/actos-lawsuit-announcemen/flood-law-group/prweb11959914.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 20, 2014 Category: Pharmaceuticals Source Type: news
Actos Lawsuit Verdict Prompts Pennsylvania Drug Lawyers to Comment
A jury in Louisiana has determined that Takeda Pharmaceuticals and Eli Lilly & Co. should pay billions of dollars for their role in covering up the serious bladder cancer risk associated with a...(PRWeb June 17, 2014)Read the full story at http://www.prweb.com/releases/2014/06/prweb11941251.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 18, 2014 Category: Pharmaceuticals Source Type: news
Adding insulin to metformin linked to higher mortality
Higher combined risk of CVD and death with insulin than with sulfonylureaRelated items from OnMedicaSugar not saturated fat is the major issue for CVDStatins linked to raised diabetes risk, study suggestsCaution urged over intensive glucose controlDaily aspirin use linked to major bleedingExperts query risks of pioglitazone (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 11, 2014 Category: UK Health Source Type: news
Judge Imposes Sanctions on Attorneys for Actos Maker Takeda: Flood Law...
Flood Law Group continues to investigate potential Actos lawsuits on behalf of patients who developed bladder cancer after taking Actos in light of the recent developments in Actos litigation.(PRWeb May 06, 2014)Read the full story at http://www.prweb.com/releases/actos-cancer-lawsuits/flood-law-group/prweb11826745.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 6, 2014 Category: Pharmaceuticals Source Type: news
Actos Jury Decision Encouraging for Bladder Cancer Patients Who Took...
A federal jury’s decision to award billions of dollars in damages to a bladder cancer patient who took Actos could mean that others in the same situation may also have a right to seek compensation.(PRWeb April 20, 2014)Read the full story at http://www.prweb.com/releases/2014/04/prweb11777797.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 20, 2014 Category: Pharmaceuticals Source Type: news
